Page 1

VERTEX Vertex Reports Third - Quarter 2021 Financial Results November 2 , 2021 -Broad pipeline advancing with recent progress marked by unprecedented VX - 880 clinical results in T1D ; Phase 2 clinical results for VX - 147 expected this quarter and for VX - 548 in Q1 2022 BOSTON -- ( BUSINESS WIRE ) -- Nov . 2 , 2021-- Vertex Pharmaceuticals Incorporated ( Nasdaq : VRTX ) today reported consolidated financial results for the third quarter ended September 30 , 2021 and raised full - year 2021 product revenue guidance to $ 7.4 to $ 7.5 billion . " Our financial performance in the third quarter was outstanding , marked by the exceptional continued growth of TRIKAFTA / KAFTRIO . Based on these results , we are again raising our 2021 product revenue guidance , and we see significant additional growth ahead as we continue to deliver this transformational medicine to more people with CF , " said Reshma Kewalramani , M.D. , Chief Executive Officer and President of Vertex . " During the last quarter , we also significantly expanded and advanced our pipeline . We announced unprecedented data from the first type 1 diabetes patient dosed with our stem cell - derived , allogeneic islet cells ( VX - 880 ) . We completed enrollment in the Phase 2 proof - of - concept study of VX - 147 in APOL1 mediated FSGS and will report results later this quarter . We also achieved target enrollment in both pivotal CTX001 studies to support our regulatory submissions next year . Finally , we made important advancements in our earlier stage pipeline and expect to submit INDs for both our CF mRNA program and type 1 diabetes cells and device program in 2022. " Third - Quarter 2021 Financial Highlights Product revenues , net TRIKAFTA / KAFTRIO SYMDEKO / SYMKEVI ORKAMBI KALYDECO GAAP operating income -Product revenues of $ 1.98 billion , a 29 % increase compared to Q3 2020 -Company raises full - year 2021 dance for product revenues to $ 7.4 to $ 7.5 billion Non - GAAP operating income GAAP net income Non - GAAP net income Three Months Ended September 30 , % $ $ $ $ $ $ $ $ $ 2021 1,984 ( in millions , except per share amounts ) 1,556 81 185 162 1,055 1,188 852 926 $ $ $ $ $ $ $ $ 2020 $ 1,536 960 156 226 194 672 854 667 Change 697 29 % 57 % 39 % 28 % 33 %